BRPI1010579A2 - espiro-oxetano nucleosídeos de uracila. - Google Patents

espiro-oxetano nucleosídeos de uracila.

Info

Publication number
BRPI1010579A2
BRPI1010579A2 BRPI1010579A BRPI1010579A BRPI1010579A2 BR PI1010579 A2 BRPI1010579 A2 BR PI1010579A2 BR PI1010579 A BRPI1010579 A BR PI1010579A BR PI1010579 A BRPI1010579 A BR PI1010579A BR PI1010579 A2 BRPI1010579 A2 BR PI1010579A2
Authority
BR
Brazil
Prior art keywords
spirooxyethane
uracil nucleosides
nucleosides
uracil
spirooxyethane uracil
Prior art date
Application number
BRPI1010579A
Other languages
English (en)
Inventor
Abdellah Tahri
Koen Vandyck
Lili Hu
Pierre Jean-Marie Bernard Raboisson
Steven Maurice Paula Van Hoof
Tim Hugo Maria Jonckers
Original Assignee
Janssen Products Lp
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Products Lp, Medivir Ab filed Critical Janssen Products Lp
Publication of BRPI1010579A2 publication Critical patent/BRPI1010579A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/503Pyridazines; Hydrogenated pyridazines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18Acyclic radicals, substituted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI1010579A 2009-05-14 2010-05-11 espiro-oxetano nucleosídeos de uracila. BRPI1010579A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160215 2009-05-14
PCT/EP2010/056438 WO2010130726A1 (en) 2009-05-14 2010-05-11 Uracyl spirooxetane nucleosides

Publications (1)

Publication Number Publication Date
BRPI1010579A2 true BRPI1010579A2 (pt) 2016-03-15

Family

ID=40823307

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010579A BRPI1010579A2 (pt) 2009-05-14 2010-05-11 espiro-oxetano nucleosídeos de uracila.

Country Status (38)

Country Link
US (2) US8481510B2 (pt)
EP (2) EP2430035B1 (pt)
JP (2) JP5778135B2 (pt)
KR (1) KR101806837B1 (pt)
CN (1) CN102439024B (pt)
AP (1) AP2783A (pt)
AR (1) AR076579A1 (pt)
AU (1) AU2010247439B2 (pt)
BR (1) BRPI1010579A2 (pt)
CA (1) CA2760329C (pt)
CL (1) CL2011002859A1 (pt)
CO (1) CO6440533A2 (pt)
CR (1) CR20120297A (pt)
CY (2) CY1114081T1 (pt)
DK (2) DK2511282T3 (pt)
EA (1) EA022084B1 (pt)
EC (1) ECSP11011461A (pt)
ES (2) ES2477598T3 (pt)
HN (1) HN2011003014A (pt)
HR (2) HRP20130554T1 (pt)
IL (1) IL215955A (pt)
JO (1) JO3027B1 (pt)
ME (1) ME01478B (pt)
MX (1) MX2011012027A (pt)
MY (1) MY157018A (pt)
NI (1) NI201100197A (pt)
NZ (1) NZ596073A (pt)
PL (2) PL2430035T3 (pt)
PT (2) PT2511282E (pt)
RS (1) RS52822B (pt)
SG (1) SG175981A1 (pt)
SI (2) SI2511282T1 (pt)
SM (2) SMT201300078B (pt)
TW (1) TWI461432B (pt)
UA (1) UA105790C2 (pt)
UY (1) UY32642A (pt)
WO (1) WO2010130726A1 (pt)
ZA (1) ZA201108309B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
US9012428B2 (en) 2010-11-10 2015-04-21 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
US9006209B2 (en) 2010-11-10 2015-04-14 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
AU2015252113B2 (en) * 2010-11-30 2017-05-04 Gilead Pharmasset Llc Compounds
PT3042910T (pt) * 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
WO2012142523A2 (en) * 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
KR101857337B1 (ko) * 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
WO2014194826A1 (zh) * 2013-06-06 2014-12-11 南京圣和药业有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
EP3074412A4 (en) * 2013-11-28 2017-05-31 Janssen Sciences Ireland UC Crystal form of nucleoside inhibitor of hcv
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4135716A1 (en) * 2020-04-14 2023-02-22 Janssen Pharmaceuticals, Inc. Spirocyclic nucleoside analogues for the treatment of hepatitis e
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ, インコーポレイテッド 有利な抗hcv併用療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3487A1 (fr) * 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
JP5080973B2 (ja) * 2004-06-24 2012-11-21 メルク・シャープ・エンド・ドーム・コーポレイション Rna依存性rnaウイルスの感染を処置するためのヌクレオシドアリールホスホルアミダート
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
JP2009526850A (ja) * 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Rna依存性rnaウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان

Also Published As

Publication number Publication date
ME01478B (me) 2014-04-20
EP2430035B1 (en) 2013-04-03
KR101806837B1 (ko) 2017-12-08
EA201171406A1 (ru) 2012-05-30
WO2010130726A1 (en) 2010-11-18
TW201100442A (en) 2011-01-01
CY1114081T1 (el) 2016-07-27
EP2511282A1 (en) 2012-10-17
ECSP11011461A (es) 2012-02-29
NZ596073A (en) 2013-02-22
US20130217648A1 (en) 2013-08-22
SMT201300078B (it) 2013-09-06
AP2011005958A0 (en) 2011-10-31
PT2511282E (pt) 2014-07-11
SG175981A1 (en) 2011-12-29
HK1166326A1 (en) 2012-10-26
AP2783A (en) 2013-10-31
AU2010247439B2 (en) 2014-09-25
RS52822B (sr) 2013-10-31
JO3027B1 (ar) 2016-09-05
JP2015180692A (ja) 2015-10-15
ES2411086T3 (es) 2013-07-04
CL2011002859A1 (es) 2012-07-20
CY1115383T1 (el) 2017-01-04
DK2430035T3 (da) 2013-05-27
CN102439024B (zh) 2014-09-17
AR076579A1 (es) 2011-06-22
UA105790C2 (uk) 2014-06-25
PL2430035T3 (pl) 2013-08-30
UY32642A (es) 2010-11-30
IL215955A0 (en) 2012-01-31
SI2511282T1 (sl) 2014-09-30
CN102439024A (zh) 2012-05-02
MX2011012027A (es) 2012-02-28
HRP20140605T1 (hr) 2014-09-26
DK2511282T3 (da) 2014-07-07
HRP20130554T1 (xx) 2013-07-31
MY157018A (en) 2016-04-15
JP5778135B2 (ja) 2015-09-16
KR20120018355A (ko) 2012-03-02
CO6440533A2 (es) 2012-05-15
ES2477598T3 (es) 2014-07-17
US20120065156A1 (en) 2012-03-15
CR20120297A (es) 2012-10-25
ZA201108309B (en) 2013-04-24
JP2012526764A (ja) 2012-11-01
PL2511282T3 (pl) 2014-09-30
SI2430035T1 (sl) 2013-08-30
PT2430035E (pt) 2013-05-22
IL215955A (en) 2015-03-31
TWI461432B (zh) 2014-11-21
AU2010247439A1 (en) 2011-12-01
NI201100197A (es) 2012-05-28
US8481510B2 (en) 2013-07-09
CA2760329C (en) 2017-10-31
HN2011003014A (es) 2014-06-30
EA022084B1 (ru) 2015-10-30
CA2760329A1 (en) 2010-11-18
SMT201400085B (it) 2014-09-08
EP2511282B1 (en) 2014-04-02
EP2430035A1 (en) 2012-03-21
US8933052B2 (en) 2015-01-13

Similar Documents

Publication Publication Date Title
BRPI1010579A2 (pt) espiro-oxetano nucleosídeos de uracila.
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0922681A2 (pt) nucleiotídeos de uracil ciclopropila
SMT201600351B (it) Composti antivirali
PT2231689T (pt) Novos nucleósidos 7-deazapurina citostáticos
BRPI1013760A2 (pt) compostos anticâncer de amino pirimidina.
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
DK2154967T3 (da) Pyrimidinderivater
BRPI0922508A2 (pt) Análogos de nucleosídeo
BRPI0914544A2 (pt) derivados de pirimidona substituídos
EP2435147A4 (en) GESTURE TRAINER
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BRPI1013493A2 (pt) composto de pirimidina
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI1014802A2 (pt) pró-fármacos de triptolida.
BRPI1014388A2 (pt) preparação de sólido.
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
IT1396487B1 (it) Convogliatore.
BRPI1013157A2 (pt) meio de fixação.
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
FR2947857B1 (fr) Agencement de deshuileur
BRPI0811094A2 (pt) Derivados de heteroarilamida pirimidona
BRPI1011794A2 (pt) compartimento.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time